UCB: tops BEL 20 index on broker uograde
(CercleFinance.com) - UCB's stock was the biggest (and almost only) winner in Brussels' BEL 20 index on Friday, following an upgrade - to buy - by analysts at Jefferies.
The Belgian pharmaceutical group's shares closed up over 3.5%, streets ahead of both the health sector (down 1.8%) and the BEL index (-2.1%).
In report on Friday, analysts at Jefferies were optimistic, after talks with doctors, about the upcoming launch of Bimzelx, for the treatment of hidradenitis suppurativa.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The Belgian pharmaceutical group's shares closed up over 3.5%, streets ahead of both the health sector (down 1.8%) and the BEL index (-2.1%).
In report on Friday, analysts at Jefferies were optimistic, after talks with doctors, about the upcoming launch of Bimzelx, for the treatment of hidradenitis suppurativa.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.